Ketazocine

Source: Wikipedia, the free encyclopedia.
Ketazocine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Identifiers
  • (2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one
JSmol)
  • O=C2c1c(cc(O)cc1)[C@]3([C@H]([C@@H]2N(CC3)CC4CC4)C)C
  • InChI=1S/C18H23NO2/c1-11-16-17(21)14-6-5-13(20)9-15(14)18(11,2)7-8-19(16)10-12-3-4-12/h5-6,9,11-12,16,20H,3-4,7-8,10H2,1-2H3/t11-,16-,18+/m0/s1 checkY
  • Key:HQBZLVPZOGIAIQ-SDDDUWNISA-N checkY
  (verify)

Ketazocine (

κ opioid receptor.[1]

Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially)

endogenous
substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)

Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.

The crystal structure of ketazocine was determined in 1983.[2]

See also

References

  1. S2CID 38692038
    .
  2. doi:10.1107/S0108270183009828
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ketazocine&oldid=1194507963"